Google_______________

Routine HIV Testing is Acceptable and Feasible -- New Initiatives and Guidelines Launched for National HIV Testing Day

By Liz Highleyman

To coincide with the annual National HIV Testing Day on June 27, the Centers for Disease Control and Prevention (CDC) released data from 2 studies of rapid HIV testing in emergency care settings and at gay pride events. Both reports were published in the June 22, 2007 issue of Morbidity and Mortality Weekly Report.

The CDC has expanded its efforts to encourage routine HIV testing, given that about one-quarter of the estimated 1 million people living with HIV in the U.S. are believed to be unaware that they are HIV-infected and at risk for transmitting the virus to others.

HIV Testing in Emergency Departments

Results from the first study suggest that emergency departments (EDs) should integrate rapid HIV testing into their routine medical services. To evaluate the feasibility and acceptability of this approach, a pilot testing program was implemented in April 2004 at 2 EDs, one in Los Angeles and one in New York City; in January 2005, the program was also implemented at ED in Oakland.

The sites placed posters and brochures in their waiting and registration areas advising patients of the availability of free rapid HIV testing. Individuals who said they were HIV negative or did not know their HIV status were offered testing with written consent. Preliminary testing was conducted using the OraQuik Advance Rapid HIV-1/2 Antibody Test on either oral fluid or finger-stick blood specimens; patients with positive results received a confirmatory Western blot test.

Among 186,415 people who sought care at the 3 EDs between January 2005 and March 2006, 18.6% overall were offered rapid testing; however, this figure varied widely, from 2.1% in New York to 3.6% in Los Angeles to 47.7% in Oakland. Overall, 56.5% agreed to be tested, but this varied as well, from 52.8% in Oakland to 84.0% in New York to 98.3% in Los Angeles. Among those who agreed to receive testing, more than 99% in New York and Los Angeles, but only 38.5% in Oakland, actually did so.

Among the 9365 people tested at the 3 EDs during the study period, 1% were newly diagnosed with HIV infection. Of these 97 individuals, 88% received referrals to HIV care and treatment and completed at least 1 follow-up visit.

According to an accompanying editorial comment, "The findings in this report suggest that offering HIV testing as an integrated part of routine health-care services in EDs, rather than relying on a clinical- or risk-based approach to testing, is a feasible strategy for identifying persons with previously undiagnosed HIV infection who might not otherwise access HIV-testing services."

The authors added that if a risk-based approach had been used, nearly half of the newly diagnosed individuals in this study (48%) would not have been offered testing.

Testing at Gay Pride Events

The second study assessed the feasibility of rapid HIV testing of racial and ethnic minority men who have sex with men (MSM) at gay pride events. Between 2004 and 2006, rapid testing was offered at black gay pride events in Baltimore; Charlotte; Detroit; Jackson, MS; St. Louis; and Washington, DC, Latino gay pride events in Oakland and San Francisco, and general gay pride events in Chicago and Oakland.

Among 543 attendees who reported that they had not previously tested HIV positive, 24% were given rapid tests during the events; 6% of these individuals had positive results, all of which were confirmed with Western blot tests. Among the 8 men with newly diagnosed HIV, 4 reported negative tests during the preceding year, 1 had never been tested, and 3 had an unknown testing history.

"Testing at gay pride events provides an opportunity to identify new HIV infections among MSM outside of health-care settings, particularly those from racial/ethnic minority groups," the authors concluded.

Advocates Release HIV Testing Guidelines

Numerous health, advocacy, and public service organizations held events or launched initiatives on National HIV Testing Day to encourage more people to learn their HIV status. Several of these featured celebrities and targeted underserved populations, especially blacks and Latinos.

Amid this flurry of testing encouragement, however, others sounded a note of caution. On June 26, Lambda Legal, the AIDS Foundation of Chicago, and the Center for HIV Law and Policy released a broadly endorsed set of fundamental principles to guide HIV testing policies and programs.

The group of legal and medical professionals and service providers emphasized that as efforts continue to expand HIV testing programs, testing must remain "informed, voluntary, confidential, and supported by health care."

"Expanded testing can be valuable, but it must be well planned, high quality, and client centered," said David Ernesto Munar of the AIDS Foundation of Chicago.

"We cannot lose sight of the people who will be tested," added Bebe Anderson, Lambda Legal's HIV Project Director. "Respect for the civil and human rights of patients must be at the heart of successful efforts to increase testing."

Click here for the full report.

06/29/07

Sources

EE Telzak, F Grumm, J Coffey, and others. Rapid HIV Testing in Emergency Departments -- Three U.S. Sites, January 2005-March 2006. Morbidity and Mortality Weekly Report 56(24): 597-601. June 22, 2007.

T Dowling, O Macias, D Sebesta, and others. Rapid HIV Testing Among Racial/Ethnic Minority Men at Gay Pride Events -- Nine U.S. Cities, 2004-2006. Morbidity and Mortality Weekly Report 56(24): 602-604. June 22, 2007.

Kaiser Family Foundation. HIV/AIDS Initiatives Targeting At-Risk Groups To Launch on National HIV Testing Day. Daily HIV/AIDS Report. June 27, 2007.

Lambda Legal. HIV Legal, Medical and Service Providers Launch Guide to HIV Testing. Press release. June 26, 2007.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Index of All HIV and AIDS
Articles by Topic ( A to Z)


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva
(Fosamprenavir)
Norvir (ritonavir)
Prezista
(darunavir)
Reyataz (atazanavir)
Viracept
(nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (AZT+ 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor (delavirdine)

Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors
Fuzeon (enfuvirtide; T-20)

Fixed-dose Combinations
Atripla
(efavirenz + emtricitabine + tenofovir)
Combivir
(retrovir + lamivudine)

Trizivir
(abacavir + zidovudine + lamivudine)
Truvada
(tenofovir + emtricitabine)